Development of orally administered insulin-loaded polymeric-oligonucleotide nanoparticles:statistical optimization and physicochemical characterization by Wong, Chun Y et al.
                          Wong, C. Y., Martinez, J., Zhao, J., Al-Salami, H., & Dass, C. R.
(2020). Development of orally administered insulin-loaded polymeric-
oligonucleotide nanoparticles: statistical optimization and
physicochemical characterization. Drug Development and Industrial
Pharmacy. https://doi.org/10.1080/03639045.2020.1788061
Peer reviewed version
Link to published version (if available):
10.1080/03639045.2020.1788061
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Taylor and Francis at https://www.tandfonline.com/doi/full/10.1080/03639045.2020.1788061. Please refer to
any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/user-guides/explore-bristol-research/ebr-terms/
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=iddi20
Drug Development and Industrial Pharmacy
ISSN: 0363-9045 (Print) 1520-5762 (Online) Journal homepage: https://www.tandfonline.com/loi/iddi20
Development of orally administered insulin-
loaded polymeric-oligonucleotide nanoparticles:
statistical optimization and physicochemical
characterization
Chun Y. Wong, Jorge Martinez, Jian Zhao, Hani Al-Salami & Crispin R. Dass
To cite this article: Chun Y. Wong, Jorge Martinez, Jian Zhao, Hani Al-Salami & Crispin R. Dass
(2020): Development of orally administered insulin-loaded polymeric-oligonucleotide nanoparticles:
statistical optimization and physicochemical characterization, Drug Development and Industrial
Pharmacy, DOI: 10.1080/03639045.2020.1788061
To link to this article:  https://doi.org/10.1080/03639045.2020.1788061
Accepted author version posted online: 28
Jun 2020.
Submit your article to this journal 
View related articles 
View Crossmark data
 Development of orally administered insulin-loaded polymeric-oligonucleotide nanoparticles: 
statistical optimization and physicochemical characterization 
 
Chun Y. Wong
a,b
, Jorge Martinez
a
, Jian Zhao
c,d,e
, Hani Al-Salami
f
, Crispin R. Dass
a,b,* 
 
aSchool of Pharmacy and Biomedical Sciences, Curtin University, Bentley 6102, Australia  
bCurtin Health Innovation Research Institute, Bentley 6102, Australia 
cMRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK 
dNIHR Bristol Biomedical Research Centre, University of Bristol, Bristol, UK 
ePopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK 
f
Biotechnology and Drug Development Research Laboratory, School of Pharmacy and Biomedical Sciences, 
Curtin Health Innovation Research Institute, Bentley 6102, Australia 
 
OCID: 
Chun Y. Wong: https://orcid.org/0000-0001-6132-6432 
Hani Al-Salami: https://orcid.org/0000-0003-0049-6969 
Crispin R. Dass: https://orcid.org/0000-0001-7087-7957 
 
* Corresponding author:  
Mail | Professor Crispin R. Dass,  
School of Pharmacy and Biomedical Sciences,  
Curtin University,  
GPO Box U1987,  
Perth 6845,  
Australia. 
 
Email | Crispin.Dass@curtin.edu.au  
Phone | +61 8 9266 1489   
 
Running title: Evaluation of oligonucleotide-polymeric nanoparticles 
 
Key words: chitosan, insulin, nanoparticles, oligonucleotide, polymer, protein 
  
A
ce
pte
d M
an
us
cri
pt
Abstract 
 
Introduction: Therapeutic peptides are administered via parenteral route due to poor absorption in 
the gastrointestinal (GI) tract, instability in gastric acid and GI enzymes. Polymeric drug delivery 
systems have achieved significant interest in pharmaceutical research due to its feasibility in 
protecting proteins, tissue targeting and controlled drug release pattern.  
 
Materials and Methods: In the present study, the size, polydispersity index and zeta potential of 
insulin-loaded nanoparticles were characterized by dynamic light scattering and laser doppler 
micro-electrophoresis. The main and interaction effects of chitosan concentration and Dz13Scr 
concentration on the physicochemical properties of the prepared insulin-loaded nanoparticles (size, 
polydispersity index and zeta potential) were evaluated statistically using Analysis of Variance. A 
robust procedure of reversed-phase high-performance liquid chromatography was developed to 
quantify insulin release in simulated GI buffer.  
 
Results and Discussion: We reported on the effect of two independent parameters, including 
polymer concentration and oligonucleotide concentration, on the physical characteristics of particles. 
Chitosan concentration was significant in predicting the size of insulin-loaded CS-Dz13Scr particles. 
In terms of zeta potential, both chitosan concentration and squared term of chitosan were significant 
factors that affect the surface charge of particles, which was attributed to the availability of 
positively-charged amino groups during interaction with negatively-charged Dz13Scr. The 
excipients used in this study could fabricate nanoparticles with negligible toxicity in GI cells and 
skeletal muscle cells. The developed formulation could conserve the physicochemical properties 
after being stored for 1 month at 4
 o
C.  
 
Conclusion: The obtained results revealed satisfactory results for insulin-loaded CS-Dz13Scr 
nanoparticles (159.3 nm, pdi 0.331, -1.08 mV). No such similar study has been reported to date to 
identify the main and interactive significance of the above parameters for the characterization of 
insulin-loaded polymeric-oligonucleotide nanoparticles. This research is of importance for the 
understanding and development of protein-loaded nanoparticles for oral delivery. 
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1. Introduction  
 
Oral drug administration is deemed to be a patient acceptable, convenient and safe route [1]. 
However, therapeutic peptides are administered via parenteral route due to poor absorption in the 
gastrointestinal (GI) tract, instability in gastric acid and GI enzymes [2]. Subcutaneous injections of 
therapeutic agents cause a number of negative clinical implications, for instance, occasional 
overdose, inconvenience due to multiple daily administration, and local skin adverse effects. 
Recently, sub-micron sized drug delivery systems have achieved significant interest in 
pharmaceutical research due to its feasibility in tissue targeting and controlled drug release pattern. 
A substantial quantity of studies have been carried out to investigate the potential of empty 
polymeric nanoparticles [3,4] and microparticles [5] in disease management, and their secondary 
roles in encapsulation of drugs, peptides, vaccines, cells and genes. The majority of the recent 
pharmaceutical research defines "nanoparticles" and "microparticles" as particles with size smaller 
and larger than 1 µm respectively. It was suggested that particles with size greater than 5 µm remain 
in the Peyer’s patches, nevertheless particles with size smaller than 10 µm can be transported across 
the efferent lymphatics [6]. Nevertheless, oral administration of various therapeutic agents via 
polymeric nano- and microcarriers remain unsuccessful. The challenges that restrict the sub-micron 
sized drug formulations from reaching the blood circulation include large particle size, instability in 
the GI tract, and inappropriate zeta potential for GI penetration and retention [7].  
 
Owing to the large molecular weight, insulin molecules cannot diffuse across the GI tract [8,9]. In 
the present study, positively-charged chitosan and negatively-charged scrambled Dz13 sequence 
(Dz13Scr) were used to fabricate the insulin-loaded nanoparticles [10]. With the use of chitosan-
based nanoparticles, previous studies revealed that the GI permeation and oral bioavailability of 
therapeutic proteins could be improved due to the opening of tight junctions [9,11]. Chitosan is a 
natural polymer that can be acquired from partial deacetylation of chitin, which is obtained from 
crustacean shell, fungi and yeast [12]. Chitosan offers several advantages as it is one of the most 
abundant natural, biodegradable, hydrophilic, biocompatible, mucoadhesive, safe and non-
allergenic polymers [13]. Its high stability in the GI tract has gained significant attention in the 
development of oral nano-formulations such as BSA-loaded nanoparticles [14,15], insulin-loaded 
nanoparticles [15-17], cryptdin-2-loaded nanoparticles [18], iron-lactoferrin-loaded nanoparticles 
[19-23], hepatocyte growth factor-loaded nanoparticles [24], and granulocyte colony-stimulating 
factor [25]. Oligochitosan, which is a naturally degraded product of chitosan, can preserve the 
favourable characteristics of chitosan and has been used to prepare insulin-loaded decanoic acid-
grafted oligochitosan nanoparticles. The nanoparticles that were prepared by oligochitosan could 
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lower the blood sugar level, present low toxicity in vivo and facilitate the transportation of insulin 
across the GI tract. Pure chitosan nanoparticles and microparticles demonstrated beneficial effects 
including suppression of gastric [26] and liver cancer cells, inhibition of bacterial growth [27], and 
immune response regulation [28]. When therapeutic agents were entrapped in chitosan 
nanoparticles and microparticles [29], they were found to be effective in targeting breast cancer 
cells [30], management of blood sugar level [31], and diuresis [32]. Chitosan and its derivatives was 
also effective in activating immune response, suppressing tumour growth [33], stimulating cytokine 
production [34,35] and forming circulating antibody [36]. A substantial number of research articles 
report the effectiveness of chitosan-based nanoparticles in cancer [37,38] by promotion of immune 
response, or a reduction in side-effects when co-administered with monoclonal antibodies [39].  
 
Dz13 is a DNAzyme that has been reported to be effective in inducing apoptosis, suppressing 
angiogenesis activity of various tumour cells and neointima formation [40]. It can resist 
exonuclease degradation due to 3′-3′ linked nucleotide modification [41,42]. Dz13 is not stable in 
the mouse and human serum [43]. Such limitation may have negative impacts on the stability of 
parenteral formulations, but not the development of orally administered nanoparticles as the 
entrapped drugs should be released from the destabilised drug delivery system for GI absorption. 
Dz13 and Dz13Scr (scrambled Dz13 sequence or catalytically inactive form of Dz13) were stated to 
be harmless to normal healthy cells [44]. They are deemed to be non-toxic and non-immunogenic 
gene-silencing agents [45]. Both in vitro and in vivo studies demonstrated that Dz13 and Dz13Scr 
did not elicit the activation of innate immune cells [46-48]. In clinical trial, Dz13 and Dz13Scr were 
well tolerated and patients did not present any serious adverse events [49]. One of the previous 
studies reported that doxorubicin-loaded Dz13 or Dz13Scr nanoparticles were safe in vivo with 
minimal toxicity in normal cells for clinical management of bone cancer [44]. Upon storage of the 
chitosan-Dz13 nanoparticles, the formulation could maintain its stability for at least 1 month [43]. 
 
According to the database from U.S. National Library of Medicine (that is, ClinicalTrials.gov 
database), to date, only two parenteral protein-based nanoformulations, including RSV-F protein 
nanoparticle vaccine and albumin-bound rapamycin, have been examined in clinical trials [50]. 
Previous review indicated that at least 100 insulin-loaded nanoparticulate formulations have been 
developed in the previous two decades [10]. However, the clinical translation of orally administered 
protein-based nanoparticles remains unsuccessful, and none of the formulations have been approved 
by the Food and Drug Administration [51]. Hence, there is a need to explore the use of novel 
excipients and their potential in developing orally administered insulin-loaded nanoparticles. In this 
study, encapsulation of insulin within the CS-Dz13Scr nano- and microcarriers was carried out.  
Ac
ce
pte
d M
an
us
rip
t
Peptide encapsulation in sub-micron sized drug delivery system was suggested to be one of the 
approaches in increasing the oral bioavailability of the therapeutic agents. An extensive number of 
in vitro studies reported that biopolymers such as chitosan and alginate could withstand enzymatic 
degradation in the GI tract [10]. Table 1 illustrate the insulin-loaded nanoparticulate formulations 
that have previously adopted the mathematical approaches to evaluate the physicochemical 
properties and understand the formulation characteristics. These formulations include insulin-loaded 
poly (3-hydroxybutyrate-co-3-hydroxyvalerate) nanoparticles [52], lyophilized insulin-loaded N, N-
dimethyl-N-octyl chitosan nanoparticles [53], lyophilized insulin-loaded modified chitosan 
nanoparticles [8], insulin-loaded chitosan/arabic gum nanoparticles [12,54], insulin-loaded modified 
chitosan nanoparticles [55], insulin-loaded chitosan/albumin-coated alginate/dextran nanoparticles 
[56], and insulin-loaded poly-epsilon-caprolactone/ Eudragit RS1 nanoparticles [57]. Currently, 
there is no comprehensive research available on the physicochemical characterization and statistical 
evaluation of insulin-loaded polymer-oligonucleotide nanoparticles.  
 
In our experiments, complex coacervation was used for particle synthesis. Compared to modified 
solvent emulsification-evaporation method [58] and nanoprecipitation [59], the technique used in 
the study do not involve organic solvents and sonication that are harmful to labile therapeutic 
agents. Statistical evaluation was used to examine the effect of individual independent variables as 
well as their mutual interactions on the experimental response of insulin-loaded nanoparticles 
[55,60-62]. The relationship between independent variables and outcome of drug formulation can 
be visualised by response surface plots. The effect of the following critical variables, including 
polymer concentration and oligonucleotide concentration, on the formation of particles were 
investigated. This statistical evaluation provided an insight in the developmental stage, for instance, 
the main independent effects, interaction effects and quadratic effects, of polymeric-oligonucleotide 
nanoparticulate formulations. The stability of the formulation was examined by the conservation of 
physicochemical properties and fourier-transform infrared spectroscopy (FTIR) after the 
nanoparticles were being stored for 1 month. The encapsulation efficiency and drug release profile 
of insulin were analysed by reversed-phase high-performance liquid chromatography (RP-HPLC). 
Last but not least, the cytotoxicity of the developed formulation was characterized. 
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2. Materials and methods 
 
2.1 Materials 
 
Low molecular weight (LMW) chitosan (95% deacetylated; MW 150 kDa) and Dz13Scr were 
obtained from Sigma-Aldrich (St Louis, MO, USA). Insulin was purchased from Gibco (Fort Worth, 
TX, USA). Trifluoroacetic acid (Sigma-Aldrich), acetonitrile (Thermofisher, VIC, Australia) and 
Milli-Q water used in the experiments were of pharmaceutical and analytical grade. 
 
2.2 RP-HPLC for insulin testing 
 
The protocol for insulin quantification was developed using a Shimadzu HPLC LC-20AT system 
(Kyoto, Japan) coupled with a UV-Vis detector [63,64]. The chromatographic runs were operated 
using Apollo C18 column (Maryland, USA) with 5 μm particle size (4.6 mm inner diameter × 150 
mm length) at a flow rate of 1 mL/min. The UV-Vis detection wavelength was 214 nm. The mobile 
phase consisted of solution A (Mill-Q water) and solution B (0.1% TFA in acetonitrile). The 
gradient elution of solution B was pumped from 10 to 90% in 9 minutes. A stock insulin solution of 
1.2 mg/mL was freshly prepared using Mill-Q water. The stock solution was used for the 
preparation of 8 standard solutions at concentrations of 2.97, 6.06, 12.13, 24.25, 48.5, 80.81, 121.25, 
and 202.06 µg/mL. A calibration curve was drawn by plotting the peak areas of each standard 
solution against the known insulin concentration. 
 
2.3 Preparation of insulin-loaded CS-Dz13Scr nanoparticles 
 
Insulin-loaded CS-Dz13Scr nanoparticles were manufactured by vortex-assisted complex 
coacervation [65-67]. In this study, insulin stock solution (20.9 µM) was prepared by dissolving the 
powder in Milli-Q water, followed by subsequent dilution to 100 nM by Milli-Q water. Then, 100 
µL insulin (100 nM) was added to an equal volume of Dz13Scr (5, 10 or 15 µg; in 50 mM SS buffer, 
pH 6.15) with gentle mixing. Then, chitosan solution (0.00004, 0.00025, 0.0004, 0.0025, 0.004, 
0.025, 0.04 or 0.25%; in 25 mM SA buffer, pH 7) was added. The following experimental 
conditions, including microfuge tube size (600 µL), preparation time (30 second) and speed (40 
Hertz), were used to prepare the insulin-loaded nanoparticles. Before storing the samples in the 
fridge at 4 °C for further experimentation, 30 minutes were allocated for insulin-loaded CS-
Dz13Scr nanoparticles/microparticles to stabilize. All samples were prepared in triplicates for 
physical characterization and statistical evaluation. The experiments were repeated for at least one 
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time. Figure 1 is a schematic diagram illustrating the steps for the preparation and pharmaceutical 
analysis of insulin-loaded CS-Dz13Scr nanoparticles.  
 
2.4 Physicochemical characterization of insulin-loaded nanoparticles 
 
2.4.1 Particle size and polydispersity index measurement 
 
The size and polydispersity index of formulated nanoparticles were examined. Prior to 
measurement, samples were kept in the fridge at 4 °C. An ideal formulation should consist of small 
(<500 nm) and uniform particles to facilitate mucosal absorption and enhance drug bioavailability. 
In this study, the mean size of the prepared particles was determined by dynamic light scattering 
[2,68]. A scattering angle of 90° was used to measure the particle size. The results were reported as 
mean ± SD. The homogeneity of the formulated particles was also determined. 
 
2.4.2 Zeta-potential measurement 
 
The zeta-potential of the prepared particles were determined using laser doppler micro-
electrophoresis using a Zetasizer ZSP (Malvern Instruments Ltd., UK) [69,70]. Samples were 
prepared in triplicates for measurement and the experiment was repeated for at least one time. In 
brief, 300 µL of nanoparticles or microparticles were suspended in 300 µL sterile Milli-Q water at 
room temperature, followed by filling in the folded capillary cell (DTS1070). The electric field 
strength of 5 V/cm was used to record the zeta potential at room temperature. The data was 
generated by Zetasizer software (Version 7.11). The results were reported as mean ± SD. 
 
2.5 Statistical evaluation of insulin-loaded nanoparticles 
 
According to previous literature (Table 1), the concentration of nanoparticle excipients, such as 
polyvinyl alcohol [52] and N-dimethyl-N-octyl chitosan [53], are considered to be critical 
independent variables that can influence the physicochemical properties (e.g. particle size, 
polydispersity index) of nanoparticles. The effect of independent variables (polymer concentration 
as X1, oligonucleotide concentration as X2) on the response variables (size as Y1, polydispersity 
index as Y2 and zeta potential as Y3) was examined. Insulin-loaded nanoparticles were prepared 
according to all combination of chitosan concentration (0.00004, 0.00025, 0.0004, 0.0025, 0.004, 
0.025, 0.04 or 0.25%) and Dz13Scr concentration (5, 10 or 15 µg) in triplicates. After preparation 
of insulin-loaded nanoparticles, the response variables were obtained by using dynamic light 
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scattering and laser doppler micro-electrophoresis as mentioned previously (n = 3). We fitted the 
data using a linear model with quadratic polynomial terms, where the main and interaction effects 
of (polymer concentration and oligonucleotide concentration) on response variables (size, 
polydispersity index and zeta potential) were estimated. A coefficient of determination (R
2
) was 
also estimated to illustrate how much variation of the response variables was explained by these 
independent variables [8,52,53]. The model goodness of fit was assessed by R
2
 and lack of fit value. 
P-value less than 0.05 was used as statistical significance threshold for assessing effect sizes 
estimated using Analysis of Variance (ANOVA) in Design-Expert 10. The formulated equation is 
considered to be acceptable with no significant lack of fit (p-value > 0.05). Three-dimensional 
surface response plots were drawn to illuminate the association between independent variables and 
dependent experimental responses in a graphical manner. These diagrams are valuable in clarifying 
the relationship between the input variables and outcome of interest. 
 
2.6 Conservation of the physicochemical properties 
 
As 0.004% chitosan (in 25 mM SA buffer) and 10 µg of Dz13Scr (in 50 mM SS buffer) could 
produce insulin-loaded nanoparticles with the smallest particle size and reasonable polydispersity 
index, such combination was selected for further investigation in stability analysis, FTIR analysis, 
morphology examination, encapsulation efficiency analysis, drug release study and cytotoxicity 
examination. To determine the stability of the developed insulin-loaded nanoparticles, the 
formulation was stored at 4
 o
C for 1 month. The physicochemical properties of the nanoparticles, 
including particle size, polydispersity index and zeta potential, were assessed after being stored for 
1 month.  
 
2.7 Fourier transform infrared (FTIR) spectroscopic analysis  
 
ATR-FTIR analysis (FTIR spectrometer spectrum two with UATR two accessory, Perkin-Elmer, 
Buckinghamshire, England) was conducted by scanning the samples from 4000 to 450 cm
-1
 at room 
temperature [63,71-76]. The spectra of 100 nM insulin, 100 nM of insulin-loaded CS-Dz13Scr 
nanoparticles, and 100 nM of insulin-loaded CS-Dz13Scr nanoparticles (after 1-month storage) 
were obtained using the attenuated total reflection (ATR) mode at room temperature. The 
characteristic peaks of insulin and insulin-loaded nanoparticles were examined to evaluate the 
stability of the formulation as well as the interaction between insulin and excipients in the 
formulation [52]. The in-built software (Spectrum, Perkin-Elmer) was utilized for double 
subtraction [8] and ATR correction.  
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 2.8 Morphological characterization 
 
The morphology of the insulin-loaded CS-Dz13Scr nanoparticles was examined by scanning 
electron microscopy (Zeiss Neon 40EsB, Germany) at 3kV. Prior to scanning, the nanoparticle 
samples (10 μL) were dried on to aluminium stubs and coated with platinum [77-79]. 
 
2.9 Encapsulation efficiency and drug release study 
  
The nanosuspension was centrifuged at 18200 rpm for 15 minutes (Eppendorf 5702 Centrifuge, 
Beckman Coulter, Hauppauge, NY, USA), followed by withdrawal of supernatants. The 
encapsulation efficiency of insulin-loaded CS-Dz13Scr nanoparticles was determined using the 
developed RP-HPLC protocol (section 2.2). Insulin release from CS-Dz13Scr nanoparticles was 
examined in simulated gastric fluid (hydrochloric acid; pH 2) and simulated intestinal fluid 
(phosphate buffer; pH 6.8) [11,72,80] by using an orbital shaker (PSU-20i, Biosan, Riga, Latvia; 
100 rpm; 37 ± 0.5 
o
C) at concentrations of 12.31 µg/mL. Aliquot (55 µL) was withdrawn at 0.5 hr, 
1 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 8 hr and 10 hr. After ultracentrifugation, 50 µL of sample was 
injected into RP-HPLC and the insulin release profile was determined [67]. 
 
2.10 Cell culture 
 
HT29 cells (human epithelial colorectal adenocarcinoma cells) at passage number of 8-11 and 
C2C12 cells (mouse myoblasts) at passage number of 10-13 were provided from the American 
Type Culture Collection (USA). The cells were cultured on T-75 flasks at 37 °C and incubated in a 
humidified CO2CELL 170 incubator (MMM, Germany) containing 5% CO2 and 95% air. The cell 
culture medium contained Dulbecco's Modified Eagle Medium, supplemented with fetal bovine 
serum (10% v/v), sodium bicarbonate (1.5 g/L), and penicillin-streptomycin (100 U/mL, 1% v/v) 
[81,82]. The cell culture medium was changed every second day. 
 
2.11 Cytotoxicity 
 
The cytotoxicity of insulin-loaded nanoparticles was assessed by HT29 cells and C2C12 cells by 
using Cell-Titre Blue assay (Promega, NSW, Australia). The HT29 cells were seeded in 96-well 
culture plates (Nunc, Denmark) at 1 x 10
5 
 cells/well until the formation of cell monolayer [83]. In 
Dulbecco's Modified Eagle Medium (without FBS), the HT29 cells were treated with blank medium 
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(negative control), free insulin (100 µg/mL), Dz13Scr (10 µg), chitosan (0.004%) and insulin-
loaded nanoparticles (containing 100 µg/mL insulin) for 24 hours. Also, the C2C12 cells were 
seeded in 96-well cell culture plate at 1 x 10
5
 cells/well for 24 h to ascertain cell attachment [84]. 
The C2C12 cells were exposed to the blank medium (negative control), free insulin (100 nM), 
Dz13Scr (10 µg), chitosan (0.004%) and insulin-loaded nanoparticles (containing 100 nM insulin) 
for 24 hours. After sample treatment, the cells were washed with phosphate buffer saline. The 
cytotoxicity assay was conducted by the established protocol from manufacturer. The cell viability 
was presented in percentage in relative to non-treated cells. 
 
 
3. Results and discussion 
 
In the present study, the nanoparticles were prepared by complex coacervation to achieve the 
essential information. The independent linear effects and interaction effects of 2 manipulated 
parameters on the dependent responses (particle size, zeta potential and polydispersity index) were 
acquired. In food science and pharmaceutical research, polynomial equations and RSM plots have 
been widely employed to evaluate the outcomes of interest. In terms of drug delivery, small and 
uniform particles with appropriate surface charge and drug release characteristic are ideal to 
enhance drug retention and absorption in GI tract.  
 
3.1 Preparation of insulin-loaded nanoparticles 
 
Nanoparticles produced by a mild coacervation method would be ideal for peptides, cells and genes 
encapsulation. Complex coacervation can lead to spontaneous formation of nanoparticles by 
oppositely charged molecules [53]. In this study, high temperature, sonication or harmful chemicals 
were not involved in the preparation of nanoparticles. This technique is simple and mild, thereby 
the conformational structure and bioactivity of peptides can be preserved by gentle encapsulation 
conditions. Chitosan concentrations ranging from 0.00004% to 0.25% and Dz13Scr amount ranging 
from 5 µg to 15 µg were adopted to optimise the insulin formulations (Table 2). 
 
3.2 Experimental conditions for the preparation of insulin-loaded nanoparticles 
 
When compared to insulin (58 kDa), bovine serum albumin (66.5 kDa) possesses comparable 
molecular weight and physicochemical properties. Due to the its relatively low cost, bovine serum 
albumin has been employed extensively as a model protein in drug development [14,85-87]. In the 
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preliminary study, bovine serum albumin was used as a model drug to prepare nanoparticles due to 
its relatively low cost as compared to insulin.  In the preliminary study, when bovine serum albumin 
was used as a model drug to prepare nanoparticles, we observed that preparation time, stirring speed 
and microfuge tube size had significant effects on the size, polydispersity index and zeta potential 
of bovine serum albumin-loaded particles (i.e. data not shown). In brief, the use of a large 
microfuge tube (1500 µL) was less preferable than small microfuge tube (600 µL) due to the 
production of large unloaded nanoparticles (> 770 nm). It is hypothesized that small-sized 
microfuge tube had a larger surface area to volume ratio for the pharmaceutical excipients to 
interact, which facilitate the formation and complexation of nanoparticles with narrower size 
distribution. Therefore, small-sized microfuge tube (600 µL) is recommended for protein 
encapsulation. In terms of preparation time, sufficient time is essential for the reaction of excipients 
and fabrication of nanoparticles [88]. In the preliminary study, a reduction in preparation time from 
30 seconds to 15 seconds could negatively impact the size (> 800 nm) and polydispersity index (> 
0.427) of bovine serum albumin-loaded nanoparticles. Last but not least, bovine serum albumin-
loaded nanoparticles (prepared by low vortexing speed; 20 Hertz) also demonstrated a significantly 
higher mean particle size than the formulation that was prepared by the speed at 40 Hertz in the 
preliminary study. Similarly, previous studies also reported that a higher stirring rate could 
accelerate the dispersion of the excipients and reduce particle size of chitosan nanoparticles [89] 
and polylactic acid nanoparticles [90]. Therefore, in the current study, small-sized microfuge tube 
size (600 µL), preparation time (30 second) and speed (40 Hertz) were applied to prepare the 
insulin-loaded nanoparticles.  
 
3.3 Physicochemical properties of insulin-loaded nanoparticles 
 
Oral bioavailability of proteins is normally low due to its instability in GI tract, mucus turnover and 
poor absorption in the intestine [91-93]. Therefore, the physical characteristics of particles are 
crucial for efficient peptide absorption in the GI tract. The particle size, polydispersity index and 
zeta potential of insulin-loaded particles were illustrated in figure 2. By adjusting the combination 
of chitosan concentration and Dz13Scr concentration, both insulin-loaded CS-Dz13Scr 
nanoparticles and insulin-loaded CS-Dz13Scr microparticles could be generated with various 
physical characteristics. Overall, the best insulin-loaded CS-Dz13Scr nanoparticles formulation, 
consisting of 0.004% chitosan and 10 µg Dz13Scr, demonstrated the smallest particle size (159.3 
nm) and a reasonable polydispersity index (0.331) (Table 2). The zeta potential of the best 
formulation was slightly negative (-1.08 mV). The particle size is deemed to be one of the main 
physicochemical features of the nanoparticles. It was reported that the permeability of the 
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nanoparticles across the GI tract increased as the particle size decreased [8,94]. The samples 
consisting of 0.0025% and 10 µg Dz13Scr would be considered as the second-best formulation. 
This formulation produced a larger particle size 234.6 nm), but the polydispersity index (0.283) and 
zeta potential (-0.56 mV) were both similar to the best formulation. Surface charge of the drug 
delivery systems is directly related to the excipients’ ratio. The zeta potential of insulin-loaded CS-
Dz13Scr nanoparticles tended to be negatively-charge for formulations with low chitosan 
concentration (0.00004% to 0.025%), or formulations containing high amount of Dz13Scr and 
0.04% chitosan. In contrast, the zeta potential of particles became positive when a higher 
concentration of chitosan (0.25%) solution was added. Thus, one can deduce that the zeta potential 
is influenced by the presence of excess chitosan on the CS-Dz13Scr particle surface.  
 
3.4 Statistical evaluation of the physicochemical characteristics of insulin-loaded 
nanoparticles 
 
Independent variables, including polymer concentration and oligonucleotide concentration, can 
interact to produce the dependent effects of nanoparticulate formulations. Previous studies 
demonstrated that the concentration of excipients (e.g. poly(hydroxybutyrate-co-hydroxyvalerate) 
[52], polyvinyl alcohol [52]) could have critical effect on the physicochemical properties of 
nanoparticles. To explore and understand the main independent effects and interaction effects of 
chitosan concentration and Dz13Scr concentration, the non-linear quadratic statistical model was 
formulated to elucidate the effect of the independent variables and their interactions on formation of 
insulin-loaded CS-Dz13Scr particles. Insulin-loaded CS-Dz13Scr particles were evaluated 
statistically by the polynomial equations that were generated by using Analysis of Variance. The 
generated quadratic model was found to be useful in predicting size (F= 5.33; p-value = 0.0035) and 
zeta potential (F = 5.19; p-value = 0.004). According to the largest absolute value of coefficients in 
equation 1, 2 and 3, chitosan concentration was the most influential factor associated with size, 
polydispersity index and zeta potential (Table 3). Results from ANOVA showed that only the 
chitosan concentration was significant (p < 0.0001) in predicting the size of insulin-loaded CS-
Dz13Scr particles. On the other hand, both chitosan concentration (p = 0.0059) and squared term of 
chitosan (p = 0.0017) were significant factors that affect the surface charge of particles (Table 3). 
This phenomenon can be attributed to the availability of positively-charged amino groups during 
interaction with negatively-charged Dz13Scr. The interaction coefficient between chitosan 
concentration and Dz13Scr amount was not significant in predicting size, polydispersity index and 
zeta potential. Figure 3 illustrates the response surface plots for insulin-loaded CS-Dz13Scr 
particles by setting 100 nM insulin as a fixed constraint. Table 3 outlines the main effect, 
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significant coefficients, impact of main and interaction parameters on the outcome responses (size, 
polydispersity index, zeta potential) for insulin-loaded CS-Dz13Scr particles. 
 
 𝑆𝑖𝑧𝑒 =
 7019.1 +  135.91X1 –  5.41X2  +  27.17X1X2  −  6137.79𝑋1 
2 –  539.55𝑋2 
2 (𝐞𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟏)  
𝑃𝑜𝑙𝑦𝑑𝑖𝑠𝑝𝑒𝑟𝑠𝑖𝑡𝑦 𝑖𝑛𝑑𝑒𝑥 =  0.53 –  0.046X1  +  0.03X2  +  0.022X1X2 –  7.142𝐸
−003𝑋1 
2  +
 1.542𝐸−003𝑋2 
2 (𝐞𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟐)  
𝑍𝑒𝑡𝑎 𝑝𝑜𝑡𝑒𝑛𝑡𝑖𝑎𝑙 =
−18.28 +  5.68X1  −  0.81X2  +  0.38X1X2  +  22.42𝑋1 
2 –  0.23𝑋2 
2 (𝐞𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟑),  
 
where X1 and X2 denote chitosan concentration and Dz13Scr amount. 
 
3.5 Stability of the physicochemical properties 
 
The stability of the physicochemical properties of the nanoparticles can influence the cellular 
interaction, GI absorption efficiency, mucus permeation and therapeutic effect of the formulation 
[95]. Therefore, the stability of the physicochemical properties has been examined extensively in 
insulin-loaded nanoparticles [96,97]. For instance, the particle size of insulin-loaded polyvinyl 
alcohol-coated nanoparticles could be maintained when the formulation was being stored for 21 
days at 4 °C [98], while the particle size of insulin-loaded hyaluronic acid-coated nanoparticles 
could  be conserved for at least 1 month under both 4 and 25 °C. In Figure 4(a), Figure 4(b) and 
Figure 4(c), the particle size, polydispersity index and zeta potential stability of the developed 
insulin-loaded nanoparticles were presented respectively. As compared to the freshly prepared 
formulation, statistical analysis revealed that the developed insulin-loaded nanoparticles did not 
present any significant difference in particle size (172.73 nm; p > 0.05), polydispersity index (0.34; 
p > 0.05) and zeta potential (-1.27 mV; p > 0.05). Therefore, the nanoparticles that were prepared 
by chitosan and Dz13Scr could maintain the stability of the formulation, and the physiochemical 
properties of nanoparticles were preserved upon storage. 
 
3.6 FTIR-ATR examination of insulin-loaded nanoparticles 
 
The functional groups of insulin-loaded CS-Dz13Scr nanoparticles were examined by FTIR-ATR 
spectroscopy. Figure 4(d) illustrates the FTIR spectra of 100 nM insulin, freshly prepared 100 nM 
of insulin-loaded CS-Dz13Scr nanoparticles and insulin-loaded CS-Dz13Scr nanoparticles (1-
month storage). In the 100 nM insulin FTIR spectra, the characteristic peaks were obtained at 1643 
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cm
-1
 (-C=O stretching) and 1558 cm
-1
 (N-H bending) for amide I band and amide II band 
respectively. The formation of insulin-loaded CS-Dz13Scr nanoparticles was confirmed, which 
demonstrated similar peak at 1642-1644 cm
-1 
and 1558 cm
-1
. The FTIR analysis revealed that 
complex coacervation had no negative impact on the stability and characteristic amide bands of 
insulin. Upon storage of the formulation for 1-month, the stability of the insulin-loaded 
nanoparticles was maintained as shown by the FTIR spectra.  
 
3.6 Encapsulation efficiency and drug release analysis of insulin-loaded nanoparticles 
 
In the present study, RP-HPLC was utilized to quantify the encapsulation efficiency of the insulin-
loaded CS-Dz13Scr nanoparticles. The RP-HPLC calibration showed good linearity for 8 standard 
solution (2.9 to 202 µg/mL) with R
2
 greater than 0.998. The encapsulation efficiency of the 
formulation was 70.72 ± 0.23 %. In Figure 5, insulin-loaded CS-Dz13Scr nanoparticles 
demonstrated a burst release profile in both SGF (31.02%) and SIF (27.87%) at 37 
o
C within 30 
minutes. It indicated that insulin desorption occurred at the surface of the nanoparticles. After initial 
rapid release, all encapsulated insulin was released at a controlled pattern over 10 hours in SGF due 
to the diffusion of the encapsulated drug from the core of nanoparticles, whereas the percentage of 
insulin released was 91.73% over 10 hours in SIF. The obtained data demonstrated that RP-HPLC 
could analyse the encapsulation efficiency and amount of insulin release from polymeric-
oligonucleotide formulations. 
 
3.7 Cytotoxic effect of insulin-loaded nanoparticles 
 
Previous studies showed that polymeric nanoparticle presented satisfactory safety profile and 
negligible toxicity [8,53,99,100]. For instance, the lyophilized insulin-loaded modified chitosan 
nanoparticles did not show any toxicity in GI cells after being treated for 3 h [8]. For the 
pharmaceutical development of insulin-loaded nanoparticles, HT29 cells [101] and C2C12 cells 
[102,103] have been used extensively as the in vitro intestinal model and in vitro insulin-responsive 
skeletal muscle cell model respectively. In the current study, as shown in Figure 6(a), all tested 
samples displayed at least 94% of HT29 cell viability. Statistical analysis by Analysis of Variance 
showed that insulin, Dz13Scr, chitosan and insulin-loaded nanoparticles had no significant 
difference in mean cell viabilities as compared to non-treated cells (negative control) (p > 0.05). 
When C2C12 cells were exposed to insulin, Dz13Scr, chitosan and insulin-loaded nanoparticles, the 
samples did not elicit any cytotoxicity to the C2C12 cells. As shown in Figure 6(b), the C2C12 cell 
viability was at least 90% after being incubated with the samples. When compared to the negative 
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control, Analysis of Variance revealed that all tested samples introduced negligible cytotoxicity to 
the C2C12 cells. Therefore, the fabricated nanoparticles and excipients in the formulation were 
biocompatible and safe at the tested concentration. 
 
3.8 Potential applications of insulin-loaded nanoparticles 
 
Nanoparticle is a promising drug delivery system that can enhance the stability and absorption of 
instable therapeutic agents by withstanding drug degradation, promoting GI adhesion and 
demonstrating controlled drug release behaviour. In this study, the insulin-loaded nanoparticles 
were loaded in the nanoparticles by complex coacervation technique using Dz13Scr and 
biodegradable chitosan with promising size and zeta potential. As shown in Figure 5, the spherical 
nanoparticles were generated in this technique. As compared to dynamic light scattering, the 
obtained particle size in scanning electron microscopy was smaller. Previous literature stated that 
the phenomenon was attributed to the removal of water molecules from the samples, which nullified 
the effect of sample swelling [97,104,105]. Insulin is an amphoteric molecule that can be 
encapsulated into the particles that are composed of chitosan and Dz13Scr. Its chemical interaction 
with polymers includes ionic, hydrogen and van der Waal’s forces. The positively-charged chitosan 
can form complexes with negatively-charged residues of Dz13Scr and insulin. In the GI tract, the 
mucoadhesiveness of chitosan-based formulation could enhance the stability and absorption of 
therapeutic peptides [106]. We reported that 0.004% chitosan and 10 µg Dz13Scr could generate a 
successful insulin-loaded CS-Dz13Scr nanoparticulate formulation with the smallest particle size 
(159.3 nm) and a reasonable polydispersity index (0.331). Previous studies demonstrated that 
particles with small size was favourable for the mucosal diffusion and GI absorption of insulin-
loaded nanoparticles [8,107,108]. 
 
This study revealed the potential of CS-Dz13Scr nanoparticulate system for oral delivery of insulin. 
Insulin is a protein with 51 amino acids commonly injected subcutaneously in the management of 
diabetes mellitus. Although various strategies have been investigated to enhance the oral 
bioavailability of peptides [91], nanoparticulate drug delivery systems remain the most attractive 
approach, due to its capacity in shielding the encapsulated therapeutic agents, and promoting drug 
absorption by both paracellular and transcellular routes [10]. However, burst release of insulin was 
observed in the drug release study for the developed formulation. The following strategies, 
including the use of enteric-coated polymeric coatings (e.g. Eudragit® FS 30D [109], 
hydroxypropyl methylcellulose phthalate  [110]), modified natural polymers (e.g. methylated 
chitosan [55]), enteric-coated tablets, and enteric-coated capsules [110], are warranted in future 
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studies. These strategies have been proven to minimise the wastage of costly protein and mitigate 
the effect of burst release. Furthermore, the immunogenicity, biocompatibility and pharmacokinetic 
response of the orally administered formulation should be examined in future studies. Apart from 
blood sugar level management, insulin-loaded CS-Dz13Scr nanoparticles can be potentially applied 
to promote tissue healing [111] in patients with chronic wounds and diabetic ulcers, which reduced 
wound healing time when incorporated into topical cream [112] and spray-based formulation [113]. 
Last but not least, insulin-loaded CS-Dz13Scr nanoparticles can be a potential drug delivery system 
to induce bone cell proliferation [114], osteoblast differentiation [115] and bone mineralization 
[116,117]. Insulin is also a hormone involving in bone energy metabolism and bone remodelling 
[118,119]. Its potential in diabetes treatment, wound healing and bone cells proliferation should be 
investigated. 
 
 
4. Conclusion 
 
In the present study, insulin-loaded CS-Dz13Scr nanoparticles were successfully prepared by 
complex coacervation. Through the self-assembling process, nanoparticles could be prepared in an 
absence of harsh chemical. The formulation was characterized in terms of particle size, 
polydispersity index and zeta potential. The physical characteristics and drug release profile of 
particles are crucial for stability, mucosal adhesion and efficient absorption. This study examined 
the effect of 2 factors, including polymer concentration and oligonucleotide concentration, that 
could influence the physical characteristics of particles. The obtained results revealed satisfactory 
results for insulin-loaded CS-Dz13Scr nanoparticles (159.3 nm, pdi 0.331, -1.08 mV). The 
pharmaceutical excipients used in the present study are known to be biodegradable, biocompatible 
and harmless to GI cells and skeletal muscle cells.  
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Table 3. The main effect, significant coefficients, impact of main and interaction parameters on the 
outcome responses (size, polydispersity index, zeta potential) for insulin-loaded CS-Dz13Scr 
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Figure 1. Schematic presentation of the preparation and pharmaceutical analysis of insulin-loaded 
nanoparticle. 
 
Figure 2. The particle size, polydispersity index and zeta potential of insulin-loaded particles. 
 
Figure 3. The response surface plot of insulin-loaded CS-Dz13Scr particles for size distribution, 
polydispersity index and zeta potential. 
 
Figure 4. The stability of physicochemical properties and FTIR spectra of insulin-loaded 
nanoparticles. 
 
Figure 5. The SEM image and drug release profile of insulin-loaded CS-Dz13Scr nanoparticles. 
 
Figure 6. The cell viabilities of HT29 cells and C2C12 cells. 
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Table 1. Statistical findings and formulation characteristics of insulin-loaded nanoparticles. 
 
Formulations Preparation 
technique 
Optimization 
method 
Summary of statistical findings and 
formulation characteristics 
Reference 
Insulin-loaded 
poly (3-
hydroxybutyrate-
co-3-
hydroxyvalerate) 
Nanoparticles 
Double 
emulsification 
solvent 
evaporation 
method 
Box Behnken 
design 
 Poly (3-hydroxybutyrate-co-3-
hydroxyvalerate) concentration had 
significant effect on the particle size and 
polydispersity index. 
 An increment in polyvinyl alcohol 
concentration to the optimum value 
reduced the particle size, but the size 
increased when the concentration 
increased beyond the optimum value due 
to the formation of large emulsion 
droplets. 
 The interaction of poly (3-
hydroxybutyrate-co-3-hydroxyvalerate) 
concentration and polyvinyl alcohol 
concentration had significant effect on 
the particle size and polydispersity index. 
 An increase in poly (3-hydroxybutyrate-
co-3-hydroxyvalerate) and polyvinyl 
alcohol concentration increased the 
polydispersity index due to the 
generation of rough dispersion. 
 FTIR spectra showed that insulin-loaded 
Nanoparticles possessed comparable 
characteristic peaks of insulin. 
2018: [52] 
Lyophilized 
insulin-loaded N, 
N-dimethyl-N-
octyl chitosan 
Nanoparticles 
Polyelectrolyte 
complexation 
Box Behnken 
design 
 The concentration of N-dimethyl-N-octyl 
chitosan had significant effect on the 
particle size and polydispersity index. 
 An increase in polymer concentration (at 
acidic pH) could increase the particle size 
and polydispersity index. 
 High polymer concentration decreased 
the polydispersity of the formulation. 
 The Nanoparticles had no cytotoxicity in 
GI cells after being treated for 5 h. 
2018: [53] 
Lyophilized 
insulin-loaded 
modified chitosan 
Nanoparticles 
Polyelectrolyte 
complexation 
D-optimal 
response 
surface 
methodology 
 High level of burst release at alkaline pH 
with more than 40% of insulin release 
within 100 min in vitro. 
 The Nanoparticles demonstrated no 
significant toxicity in GI cells after being 
treated for 3 h. 
 Methylated N-(4-N, N-
dimethylaminobenzyl) chitosan 
Nanoparticles elicited higher insulin 
absorption than trimethyl chitosan 
Nanoparticles. 
2014: [8] 
Insulin-loaded 
chitosan/arabic 
gum 
Ionotropic 
gelation 
2
3
 factorial 
design 
 High level of initial burst release (30% to 
50%) within 15 min at acidic pH. 
 Nanoparticles could facilitate the 
2011: [12] 
2010: [54] 
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Nanoparticles transportation of insulin ex vivo. 
Insulin-loaded 
modified chitosan 
Nanoparticles 
Polyelectrolyte 
complexation 
D-optimal 
response 
surface 
methodology 
 A slight increase in particle size as the 
concentrations of methylated 
(aminobenzyl), methylated (benzyl) and 
methylated (pyridinyl) chitosan increase. 
 The polymer concentration had 
significant effect on the zeta potential of 
Nanoparticles. 
 As the concentration of polymer 
increases, the polydispersity index of the 
Nanoparticles increases. 
 Polymer type had significant effect on the 
polydispersity index of the Nanoparticles. 
 Burst release of insulin was presented by 
the fabricated Nanoparticles with at least 
20% to 40% of insulin release within 50 
min. 
2011: [55] 
Insulin-loaded 
chitosan/albumin-
coated 
alginate/dextran 
Nanoparticles 
Ionotropic 
gelation 
Box Behnken 
design 
 Particle size was dependent on the 
concentration of calcium chloride, 
chitosan and albumin. 
 Polydispersity index was dependent on 
the calcium concentration, but not the 
concentration of chitosan or albumin. 
 Zeta potential was influenced by the 
concentration of chitosan due to the 
existence of positively charged amino 
groups. 
 The drug release property was dependent 
on the chitosan concentration due to the 
swelling property of chitosan. 
 The drug release property was also 
dependent on the concentration of the 
albumin concentration due to its effect on 
the strength of electrostatic interaction. 
 Burst release of insulin from the 
Nanoparticles was observed at the 
alkaline pH with more than 80% release 
after 180 min. 
2009: [56] 
Insulin-loaded 
poly-epsilon-
caprolactone/ 
Eudragis RS1 
Nanoparticles 
Water-in-oil-
in-water 
emulsification 
and 
evaporation 
method 
D-optimal 
response 
surface 
methodology 
 As the ratio of poly(epsilon caprolactone) 
to Eudragit RS decreases, the particle size 
decreases due to the surfactant behaviour 
of Eudragit RS. 
 As the ratio of poly(epsilon caprolactone) 
to Eudragit RS increases, the 
polydispersity increases. 
 An initial burst release of insulin was 
observed, followed by controlled drug 
release for 7 h. 
2005: [57] 
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Table 2. Mean particle size, polydispersity index and zeta potential of insulin-loaded CS-Dz13Scr 
nanoparticles/microparticles. 
 
  Formulations Physical characteristics 
 CS 
concentration 
Dz13Scr 
amount 
Particle size ± 
S.D (nm) 
Polydispersity 
index ± S.D 
Zeta potential ± 
S.D (mV) 
1.  
0.00004% 
5 µg 377.3  ± 61.6 0.500  ± 0.179 -1.84  ± 1.13 
2.  10 µg 290.4  ± 39.0 0.460  ± 0.027 -0.70  ± 0.30 
3.  15 µg 832.9  ± 525.2 0.893  ± 0.186 -0.90  ± 0.25 
4.  
0.00025% 
5 µg 245.3  ± 240.6 1  ± 0 -0.81  ± 0.63 
5.  10 µg 2341.8  ± 2414.4 0.764  ± 0.206 -1.21  ± 0.51 
6.  15 µg 419.9  ± 75.9 0.439  ± 0.067 -0.82  ± 0.74 
7.  
0.0004% 
5 µg 382.4  ± 84.9 0.758  ± 0.212 -1.02  ± 0.75 
8.  10 µg 380.0 ± 242.8 0.666  ± 0.282 -2.68  ± 2.98 
9.  15 µg 516.8  ± 328.7 0.712  ± 0.033 -0.53  ± 0.08 
10.  
0.0025% 
5 µg 267.7  ± 34.6 0.313  ± 0.133 -1.00  ± 0.55 
11.  10 µg 234.6  ± 41.7 0.283  ± 0.050 -0.56  ± 0.25 
12.  15 µg 201.0  ± 95.7 0.421  ± 0.209 -0.41  ± 0.03 
13.  
0.004% 
5 µg 662.2  ± 69.4 0.497  ± 0.038 -10.12  ± 2.81 
14.  10 µg 159.3  ± 8.7 0.331  ± 0.001 -1.08  ± 0.36 
15.  15 µg 203.4  ± 74.0 0.409  ± 0.155 -0.80  ± 0.75 
16.  
0.025% 
5 µg 4669.3  ± 3231.2 0.247  ± 0.122 -12.12  ± 3.35 
17.  10 µg 1942.3  ± 322.1 0.897  ± 0.047 -14.20  ± 2.21 
18.  15 µg 1566.7  ± 345.8 0.464  ± 0.182 -21.27  ± 1.21 
19.  
0.04% 
5 µg 1109.7  ± 11.0 0.575  ± 0.095 5.17  ± 0.26 
20.  10 µg 6428.3  ± 565.1 0.521  ± 0.426 -9.54  ± 1.58 
21.  15 µg 3652.3  ± 1706.6 0.723  ± 0.279 -16.90  ± 1.28 
22.  
0.25% 
5 µg 655.7  ± 20.8 0.429  ± 0.005 8.17  ± 0.34 
23.  10 µg 718.5  ± 24.2 0.504  ± 0.029 9.69  ± 0.81 
24.  15 µg 595.3  ± 14.3 0.495  ± 0.037 10.97  ± 0.75 
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Table 3. The main effect, significant coefficients, impact of main and interaction parameters on the 
outcome responses (size, polydispersity index, zeta potential) for insulin-loaded CS-Dz13Scr 
particles. 
 
Formulations Independent 
factors 
Dependent 
variables 
Summary of main findings 
Insulin-
loaded CS-
Dz13Scr 
particles 
X1 polymer 
concentration 
(0.00004, 0.00025, 
0.0004, 0.0025, 
0.004, 0.025, 0.04 
or 0.25% chitosan 
in 25 mM SA 
buffer; 100 µl) 
Size  F = 5.33 (p = 0.0035) 
 Main effects: chitosan concentration 
 Significant coefficients: chitosan concentration (p 
< 0.0001) 
 Coefficients that reduce size: Dz13Scr amount, 
chitosan concentration (quadratic term), Dz13Scr 
amount (quadratic term) 
 Coefficients that increase size: chitosan 
concentration, interaction between chitosan and 
Dz13Scr 
X2 oligonucleotide 
concentration (5, 10 
or 15 µg Dz13Scr in 
50 mM SS buffer) 
Polydispersity 
index 
 Main effects: chitosan concentration 
 Coefficients that reduce pdi: chitosan 
concentration, chitosan concentration (quadratic 
term) 
 Coefficients that increase pdi: Dz13Scr amount, 
interaction between chitosan and Dz13Scr, 
Dz13Scr amount (quadratic term) 
Zeta potential  F = 5.19 (p = 0.004) 
 Main effects: chitosan concentration 
 Significant coefficients: chitosan concentration (p 
= 0.0059), chitosan concentration (quadratic term; 
p = 0.0017) 
 Coefficients that reduce zeta potential: Dz13Scr 
amount, Dz13Scr amount (quadratic term) 
 Coefficients that increase zeta potential: 
chitosan concentration, interaction between 
chitosan and Dz13Scr, chitosan concentration 
(quadratic term) 
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Figure 1. Schematic presentation of the preparation and pharmaceutical analysis of insulin-loaded 
nanoparticle. 
 
 
  
1. Prepare  
20.9 µM 
insulin stock 
solution. 
2.Prepare 100  
µL Dz13Scr (5, 
10 or 15 µg; in 
50 mM SS 
buffer, pH 
6.15).  
3. Add 100 µL 
insulin (100 
nM) with 
gentle mixing. 
4. Add 100 µL 
chitosan 
(0.00004, 
0.00025, 
0.0004, 0.0025, 
0.004, 0.025, 
0.04 or 0.25%; 
in 25 mM SA 
buffer, pH 7).  
5. Vortex with 
small-sized 
microfuge 
tubes at 40 
Hertz for 30 s. 
Sit for 30 mins 
at R.T. 
B. Physiochemical characterization of insulin-loaded nanoparticles: Particle size, polydispersity 
index, zeta-potential 
C. Statistical evaluation of insulin-loaded nanoparticles 
D. Selection of the formulation with optimal physiochemical properties 
F. Physical characterization: Morphology, encapsulation efficiency, drug release behaviour 
A. Preparation of insulin-loaded CS-Dz13Scr NPs/MPs by complex coacervation 
E. Stability of the physiochemical properties and FTIR analysis of insulin-loaded nanoparticles 
G. Cytotoxicity analysis of insulin-loaded nanoparticles 
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Figure 2. The particle size, polydispersity index and zeta potential of insulin-loaded particles. 
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Figure 3. The response surface plot of insulin-loaded CS-Dz13Scr particles for size distribution, 
polydispersity index and zeta potential. 
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Figure 4. The stability of physicochemical properties and FTIR spectra of insulin-loaded 
nanoparticles. 
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Figure 5. The SEM image and drug release profile of insulin-loaded CS-Dz13Scr nanoparticles. 
 
 
 
Figure 6. The cell viabilities of HT29 cells and C2C12 cells. 
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